Skip to main content
. Author manuscript; available in PMC: 2013 May 3.
Published in final edited form as: Ann Neurol. 2012 Feb 28;71(3):323–333. doi: 10.1002/ana.22686

FIGURE 3.

FIGURE 3

Neutropenia reduces brain damage at 7 days after IgGNMO+ hC injection. (A) (Left) Peripheral neutrophil count. Antineutrophil (yellow) or isotype control (red) IgG was injected at days −1, 2, and 4. All mice received IgGNMO+hC at days 0, 3, and 5 and were killed on day 7. (B) H&E: non-neutropenic vs neutropenic (+anti-nφ) brain. (i) Brain parenchyma, inset = macrophage immunostain. (ii) Perivascular leukocytes, black arrowheads = mononuclear cells, red arrowheads = eosinophils, L = lumen. (C) (Left) CD45 immunostain: non-neutropenic vs neutropenic (+anti-nφ) brain. (Right) % inflammation (area-α/area-β). (D) (Left) LFB: non-neutropenic vs neutropenic (+anti-nφ) brain. (Right) % loss of myelin (area-α/area-β). (E) (Left) AQP4 immunostain: non-neutropenic vs neutropenic (+anti-nφ) brain. (Right) % loss of AQP4 (area-α/area-β). We injected 6 non-neutropenic (red), 6 neutropenic (yellow), and 5 non-neutropenic AQP4 null (blue) mice with IgGNMO+hC; 5 non-neutropenic mice received IgGCON+hC (green). Mean ± standard error. *p < 0.05, **p < 0.01, ##p < 0.0005 vs IgGNMO+hC+anti-nφ. Bar = 20 μm (B), 2 mm (C–E).